NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease

NCT03703856

CompletedPhase 4

Sponsor: University of California, San Diego

Conditions: Alzheimer Disease

Interventions: Memantine

Countries: United States

The effects of the medication, memantine, on brain functions and the symptoms of Alzheimer's Disease will be tested

Eligibility overview

Sex: ALL

Age: 50 Years to 83 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion:

1. Alzheimer's Disease Research Center-confirmed diagnosis of AD
2. Mini-Mental State Examination (MMSE) score 10-22 OR a Montreal Cognitive Assessment (MOCA) score of 15-24
3. Age 50-83 y
4. Knowledgeable caregiver
5. Ambulatory
6. Medically stable;
7. Audiometric testing (detection \< or = to 45 db(A) at 1000 Hz)
8. Informed consent

Exclusion:

1. Active systemic illness (e.g. heart disease, liver failure, renal insufficiency, cancer, HIV, tuberculosis, Hepatitis C)
2. Current psychiatric or neurologic illness other than AD
3. History of vascular disease, myocardial infarction, cerebrovascular accidents, transient ischemic attack, seizure, head injury with loss of consciousness; substance dependence (including alcohol and Opioid)
4. Past treatment with memantine; unable to tolerate acetylcholinesterase inhibitor
5. Investigational drug treatment \< 30 d of screening
6. Current meds: amantadine, riluzole, other pro-cognitive medication, opioids
7. Positive urine toxicology for non-prescribed psychoactive substance
8. Actively enrolled in cognitive remediation therapy

Locations (1)

San Diego, California, United States